Lau C P, Cheung B M
Division of Cardiology, University of Hong Kong, Queen Mary Hospital, Hong Kong.
J Cardiovasc Pharmacol. 1996 Aug;28(2):328-31. doi: 10.1097/00005344-199608000-00021.
Calcium channel blockers are increasingly used in the treatment of hypertension. Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t1/2) that permit once-daily dosage and are generally better tolerated than their parent compound. In this study, the efficacy and safety of lacidipine and amlodipine were compared in 65 patients with mild-to-moderate hypertension attending the hypertension outpatient clinic of a teaching hospital in a randomized double-blind cross-over trial with dose titration. Lacidipine and amlodipine both significantly reduced systolic blood pressure (SBP: by 19.2 +/- 13.5 and 22.3 +/- 15.3 mm Hg, respectively) and diastolic BP (DBP: 13.3 +/- 4.2 and 12.3 +/- 5.3 mm Hg, respectively) 24 h postdose. There were no significant differences in their antihypertensive effects. The incidence of adverse events (AE) was 3% for lacidipine and 8% for amlodipine. The incidence of withdrawal from the study due to side effects was 0% for lacidipine and 3% for amlodipine. These results suggest that lacidipine is well-tolerated, and is as effective as amlodipine as a once-daily antihypertensive agent.
钙通道阻滞剂在高血压治疗中的应用日益广泛。新型二氢吡啶类钙通道阻滞剂的消除半衰期（t1/2）更长，允许每日给药一次，且通常比其母体化合物耐受性更好。在本研究中，在一家教学医院高血压门诊的65例轻至中度高血压患者中，进行了一项随机双盲交叉试验并进行剂量滴定，比较了拉西地平与氨氯地平的疗效和安全性。给药24小时后，拉西地平和氨氯地平均显著降低收缩压（SBP：分别降低19.2±13.5和22.3±15.3 mmHg）和舒张压（DBP：分别降低13.3±4.2和12.3±5.3 mmHg）。它们的降压效果无显著差异。拉西地平的不良事件（AE）发生率为3%，氨氯地平为8%。因副作用退出研究的发生率，拉西地平为0%，氨氯地平为3%。这些结果表明，拉西地平耐受性良好，作为每日一次的抗高血压药物，其疗效与氨氯地平相当。
